EXELIXIS INC's ticker is EXEL and the CUSIP is 30161Q104. A total of 159 filers reported holding EXELIXIS INC in Q1 2014. The put-call ratio across all filers is 0.32 and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2017 | $375,000 | -71.7% | 17,304 | -80.5% | 0.01% | -69.7% |
| Q4 2016 | $1,325,000 | -20.7% | 88,835 | -32.0% | 0.03% | -17.5% |
| Q3 2016 | $1,670,000 | +67.3% | 130,582 | +2.2% | 0.04% | +90.5% |
| Q2 2016 | $998,000 | +135.4% | 127,802 | +20.6% | 0.02% | +75.0% |
| Q1 2016 | $424,000 | +275.2% | 106,000 | +431.3% | 0.01% | +500.0% |
| Q4 2015 | $113,000 | -26.6% | 19,950 | -66.7% | 0.00% | -33.3% |
| Q1 2015 | $154,000 | -6.7% | 59,961 | -47.6% | 0.00% | 0.0% |
| Q4 2014 | $165,000 | +768.4% | 114,349 | +839.0% | 0.00% | – |
| Q3 2014 | $19,000 | -94.5% | 12,178 | -88.1% | 0.00% | -100.0% |
| Q2 2014 | $347,000 | -53.4% | 102,541 | -51.2% | 0.01% | -44.4% |
| Q1 2014 | $744,000 | +406.1% | 210,090 | +775.4% | 0.01% | +350.0% |
| Q4 2013 | $147,000 | -13.5% | 23,998 | -17.9% | 0.00% | 0.0% |
| Q3 2013 | $170,000 | – | 29,231 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Meditor Group Ltd | 11,275,871 | $254,722,000 | 71.55% |
| GREAT POINT PARTNERS LLC | 1,201,100 | $27,133,000 | 5.61% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 886,534 | $20,027,000 | 5.30% |
| Sargent Investment Group, LLC | 498,350 | $11,258,000 | 2.96% |
| CAPITAL MANAGEMENT CORP /VA | 311,660 | $7,040,000 | 1.57% |
| EULAV Asset Management | 2,460,000 | $55,571,000 | 1.49% |
| CM Management, LLC | 80,000 | $1,807,000 | 1.34% |
| Integral Health Asset Management, LLC | 200,000 | $4,518,000 | 1.29% |
| FARALLON CAPITAL MANAGEMENT LLC | 10,750,000 | $242,843,000 | 1.21% |
| Sofinnova Investments, Inc. | 839,181 | $18,957,000 | 1.14% |